MedTrace Logo

Does Oral Pentoxifylline Administration Improve Hemoglobin in Hemodialysis Patients?

NCT03731741 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2018-11-08

No results posted yet for this study

Summary

Our study investigated the effect of using a known drug used in intermittent claudication (named pentoxifylline) as an adjuvant to erythropoietin stimulating agents to improve anemia of hemodialysis patients.

Conditions

  • Anemia of Chronic Kidney Disease

Interventions

DRUG

Pentoxifylline

a known drug of xanthine derivatives used in intermittent claudication

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • Atef Taha, M.D · Tanta university hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-01
Primary Completion
2018-05-03
Completion
2018-05-04

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03731741 on ClinicalTrials.gov